ImmunoVec develops gene therapy treatments to cure terminal genetic diseases of the immune system.
ImmunoVec has raised $12.7M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in July 2026.
ImmunoVec's investors include Advanced Research Projects Agency for Health, California Institute for Regenerative Medicine.
ImmunoVec is headquartered in Santa Monica, United States.
ImmunoVec develops gene therapy treatments to cure terminal genetic diseases of the immune system.
ImmunoVec is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ImmunoVec — Funding & Investors." VCBacked, July 14, 2026, https://www.vcbacked.co/company/immunovec. Accessed August 14, 2026.
VCBacked. (2026). ImmunoVec — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/immunovec
{{cite web |title=ImmunoVec — Funding & Investors |url=https://www.vcbacked.co/company/immunovec |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated